Opinion|Videos|June 2, 2025
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Emerging data on mHSPC shows promising trends in overall survival, highlighting the impact of care access and competing risks.
Advertisement
Episodes in this series
Overall Survival Considerations
Key Themes:
- ARANOTE’s overall survival data are still maturing.
- ARASENS data show a promising trend for survival benefit.
- Competing risks and care access issues complicate survival analysis.
- Treatment completion challenges may impact long-term outcomes.
Key Points for Physicians:
- Although definitive overall survival data are pending, trends appear promising.
- Consider social determinants and access issues that may impact long-term outcomes.
- Address potential barriers to treatment completion.
- Monitor for mature survival data as they become available.
Notable Insights: The complexity of survival analysis highlights the importance of considering factors beyond drug efficacy, particularly access to care and treatment completion, which may disproportionately affect Black patients.
Clinical Significance: Early survival trends appear promising but require longer follow-up and consideration of the broader context of care delivery and social determinants that influence outcomes.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5